Cary, N.C. , Nov. 13, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Kura Oncology as a limited specialty pharmacy provider for KOMZIFTI® (ziftomenib), an oral menin inhibitor approved for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).
“Though NPM1-mutated AML often responds well to treatment at first, it can be difficult to keep the disease under control long-term. For many patients, relapse is a heartbreaking reality,” said Ela Lourido, president of Biologics by McKesson. “Biologics by McKesson is proud to have been selected by Kura Oncology as a specialty pharmacy provider for Komzifti. As the first once-daily oral menin inhibitor targeting this mutation, Komzifti offers a new option – and new hope – for patients who have exhausted prior treatments. We’re honored to help make this therapy available and remain deeply committed to supporting patients with expert, compassionate care every step of the way.”
Acute myeloid leukemia is the most common acute leukemia in adults. It begins when the bone marrow produces abnormal white blood cells, red blood cells or platelets, and it progresses rapidly. NPM1 mutations are among the most frequent genetic alterations in AML, representing approximately 30% of cases. While patients with NPM1-mutated AML may respond to initial treatment, relapse rates are high, and survival outcomes are poor.
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for KOMZIFTI®, please click here. For more information about the treatment of patients with AML, please visit komziftihcp.com/